Pieris AG announced today the presentation of a range of in vitro and in vivo preclinical data for the company's proprietary c-Met antagonist program, PRS-110, at the American Association for Cancer Research (AACR) Annual Meeting, further establishing the compound as a differentiated next generation therapeutic protein.
Scientists at Dana-Farber Cancer Institute have discovered why diabetic-like symptoms develop in some patients given rapamycin, an immune-suppressant drug that also has shown anti-cancer activity and may even slow ageing.
To profile different tyrosine kinase (TK) expression patterns in clear cell renal carcinoma (ccRCC).
Cancer patients who receive a combination of low-dose interleukin-2 and retinoic acid after conventional therapy seem to live longer than those who don't get the combination.
Maria Teresa Fahy discusses her poster.
Scientists at Washington University School of Medicine in St. Louis are using powerful DNA sequencing technology not only to identify mutations at the root of a patient's tumor -- considered key to personalizing cancer treatment -- but to map the genetic evolution of disease and monitor response to treatment.
We are building the world's largest community for families dealing with a child's encounter with Wilms tumor, a pediatric form of kidney cancer. All are welcome to join! This effort is supported by members of the International Kidney Cancer Congress (#IKCC on Twitter).
The treatment, an antibody that blocks a "do not eat" signal normally displayed on tumor cells, coaxes the immune system to destroy the cancer cells.
In 1975, 2,953 people were diagnosed with kidney cancer in Britain. Latest figures show there were 9,042 cases in 2009, up from 8,848 in 2008.